ライフサイエンスコーパス: disease severity

1 ls of CD74 in females vs. males with high MS disease severity.

2 ally expressed proteins that correlated with disease severity.

3 e items with respect to clinical periodontal disease severity.

4 own to influence disease outcome in terms of disease severity.

5 iseased mice, and expression correlated with disease severity.

6 in the bronchial epithelium with increasing disease severity.

7 ndicating near-perfect agreement on relative disease severity.

8 linking airway microbes and host response to disease severity.

9 tients with asthma, who have a wide range of disease severity.

10 nct role from the immune system in mediating disease severity.

11 xperimental periodontitis was used to assess disease severity.

12 major exhibit similar changes depending upon disease severity.

13 tional genomic sites associated with CF lung disease severity.

14 sion in neuroblastoma tumors correlates with disease severity.

15 tion on the role of EHF in modifying CF lung disease severity.

16 se who had higher than 75% reduction in skin disease severity.

17 ile dimaprit treatment significantly reduced disease severity.

18 PF lung, with p16 expression increasing with disease severity.

19 with a two strata block design according to disease severity.

20 ssemination from the inoculation site and in disease severity.

21 ding were associated (adjusted P < .05) with disease severity.

22 als, where it augments skin inflammation and disease severity.

23 transgenic claudin-2 overexpression reduced disease severity.

24 ositively and negatively, respectively, with disease severity.

25 ) is inversely correlated with liver fat and disease severity.

26 ed VEGF expression correlates with increased disease severity.

27 quire a large study with a broad spectrum of disease severity.

28 erations that are believed to play a role in disease severity.

29 he number of targeted epitopes may determine disease severity.

30 imurium tissue colonization and consequently disease severity.

31 ss-reactive T cells have been shown to limit disease severity.

32 eding epilepsy onset are indicators of later disease severity.

33 CD4+ RSV+ T cells positively correlated with disease severity.

34 neuroinflammatory disease and contributes to disease severity.

35 tric refluxate is the primary determinant of disease severity.

36 aluate their potential use for prediction of disease severity.

37 relationship between ERRgamma expression and disease severity.

38 between antibody concentrations and clinical disease severity.

39 l, and serological parameters of chikungunya disease severity.

40 l hypometabolism is associated with clinical disease severity.

41 ole in the early control of the parasite and disease severity.

42 e SSc severity and can be used as markers of disease severity.

43 st various subtypes is necessary to mitigate disease severity.

44 dent pro-mitogenic cascade, correlating with disease severity.

45 rences between them increased with worsening disease severity.

46 derwent liver biopsy to assess the degree of disease severity.

47 n structure disturbances are correlated with disease severity.

48 (SPVL) is the most widely used predictor of disease severity.

49 ammatory phenotype bias leading to increased disease severity.

50 ance imaging, are correlated with increasing disease severity.

51 d the tPA level to positively correlate with disease severity.

52 mensional clinical outcome measure to assess disease severity.

53 as a novel therapeutic target to reduce IAV disease severity.

54 y end point was the effect of anakinra on HS disease severity.

55 of other major clinical variables, including disease severity.

56 easured, using scoring systems to categorize disease severity.

57 ive colitis (UC), and soluble ST2 (sST2), to disease severity.

58 a, hay fever, and food allergy and increased disease severity.

59 minotransferases, which was unrelated to the disease severity.

60 duce colitis model significantly accentuated disease severity.

61 n and accumulation in the intestine, and the disease severity.

62 nsistent when adjusted for confounders, like disease severity.

63 and are not able to incorporate measures of disease severity.

64 f the host inflammatory response, determines disease severity.

65 th increased mortality in patients with high-disease severity.

66 diagnostic accuracy, and is associated with disease severity.

67 ipheral tissues and correlating with overall disease severity.

68 ic cascade that produces sputum and mediates disease severity.

69 es, and the NMD pathway is known to modulate disease severity.

70 e presence of RNNIg alone cannot account for disease severity.

71 mild to severe chronic obstructive pulmonary disease severity.

72 controlling for baseline characteristics and disease severity.

73 would identify gene expression correlates of disease severity.

74 as they provide care to patients with higher disease severity.

75 h human and murine models, and correlated to disease severity.

76 whether peripheral p11 levels correlate with disease severity.

77 control individuals and were correlated with disease severity.

78 ich correlate closely with histopathological disease severity.

79 during the effector phase of EAE ameliorated disease severity.

80 rtain the underlying mechanisms of increased disease severity.

81 amples of NAFLD patients and correlated with disease severity.

82 pertussis vaccination may have an impact on disease severity.

83 member 2 rs58542926 polymorphisms influenced disease severity.

84 The level of generation correlated with the disease severity.

85 tive pregnant women were scored for clinical disease severity, 6 (4.6%) had mild disease, 98 (74.8%)

86 viral determinants might have contributed to disease severity after pandemic initiation.

87 is needed to determine if this is related to disease severity, age or other factors.

88 ed a regression model adjusting for baseline disease severity, age, and Karnofsky score, with missing

89 s diagnosed with HD (n = 11 of all grades of disease severity) along with sex- and age-matched health

90 Stratification of the ALS group for disease severity (ALS functional rating scale) confirmed

91 rt Study (VACS) Index, a composite marker of disease severity among human immunodeficiency virus (HIV

92 ents with HAP and CAP presented with similar disease severities and mortality rates did not differ up

93 No associations were found between: disease severity and abnormal outcomes (P = .961; odds r

94 developed to aid land managers in predicting disease severity and accordingly adjust their management

95 The ratio of heme to hpx is associated with disease severity and adverse clinical outcomes in Uganda

96 asymptomatic early stage and correlate with disease severity and adverse outcomes.

97 ic etiology can be a prognostic indicator of disease severity and can influence treatment decisions.

98 Disease severity and cartilage loss were evaluated by hi

99 igate the association between change in skin disease severity and change in vascular inflammation at

100 ycholesterol levels in serum correlated with disease severity and disease duration.

101 GA5 infections were associated with enhanced disease severity and distinct host immune responses.

102 The correlation between disease severity and dopamine loss appears linear, but t

103 connectivity and baseline performance, while disease severity and drug plasma level predicted the cha

104 ti in the enzootic cycle, and causes greater disease severity and duration in humans.

105 ause of PAH and comorbidities, but also with disease severity and duration.

106 sures correlated with memory performance and disease severity and duration.

107 to effectively ameliorate disease or reduce disease severity and fatalities are still needed to redu

108 e associated with ME/CFS and correlated with disease severity and fatigue duration, cytokines of 192

109 utrophil elastase activity is a biomarker of disease severity and future risk in adults with bronchie

110 c IgE found in patient serum correlated with disease severity and greatly potentiated pDC function by

111 jects with CNS cryptococcosis may help gauge disease severity and guide the therapeutic approach in t

112 arterial hypertension is important to assess disease severity and guide treatment.

113 thylation level is associated with increased disease severity and has good ability to discriminate HP

114 roach to provide important information about disease severity and helps in the detection, diagnosis,

115 ry syncytial virus (RSV) genotypes influence disease severity and host immune responses is limited.

116 RSV subtypes, genotypes, and viral loads in disease severity and host transcriptional profiles.

117 support a role for CXCL1 and IL-8 in CF lung disease severity and identify STAT3 as a modulating path

118 then challenged with the wild-type virus and disease severity and immunologic parameters were studied

119 After adjustment for disease severity and length of mechanical ventilation, d

120 investigated associations between markers of disease severity and long-term outcomes in patients with

121 ctors has been shown to significantly impact disease severity and mortality.

122 ave potential consequences for transmission, disease severity and mortality.

123 degranulation, which further contributes to disease severity and necessitates an increase in mainten

124 ve brought increasing concerns of heightened disease severity and neurotropism.

125 t risk for HFpEF, similarly associating with disease severity and outcomes.

126 The impact of FP and FN varies with disease severity and over the range of abnormal catch tr

127 al after malaria infection, but it increased disease severity and parasitemia in mice infected with P

128 Specifically, we investigate the effects of disease severity and population structure on the vaccine

129 present potential novel tissue biomarkers of disease severity and prognosis in conjunctival fibrosis

130 CCL2 expression correlates with disease severity and prognosis.

131 transcripts in patients with CMT1A serve as disease severity and progression biomarkers and, if impl

132 In order to assess and validate disease severity and progression biomarkers, we performe

133 stin degradation, are possible biomarkers of disease severity and progression in bronchiectasis.

134 spectrum of SPG5, examine the correlation of disease severity and progression with oxysterol concentr

135 he recently demonstrated correlation between disease severity and remyelination emphasizes the import

136 gher ePPIX levels are a major determinant of disease severity and risk of liver dysfunction in patien

137 patoma-derived growth factor (HDGF) with PAH disease severity and survival.

138 ive pulmonary disease (COPD) correlated with disease severity and susceptibility to exacerbations.

139 nse to systemic corticosteroids in asthma to disease severity and the baseline extent of eosinophilic

140 tions and compared with clinical measures of disease severity and the sputum microbiome.

141 This was associated with disease severity and tissue IL-5 expression but unrelate

142 95% confidence interval [CI]: 0.796-1.270); disease severity and viral load (P = .994); viral load a

143 Therefore, we tested the hypothesis that disease severity and/or bacterial loads would be signifi

144 (95% CI, .11-.28) in the TCRI (adjusted for disease severity), and 0.34 (95% CI, .16-.72) in the MAK

145 ribute to the overall clinical assessment of disease severity, and correspond to microvascular and ph

146 ella humoral immunity, did not contribute to disease severity, and did not mediate protection from co

147 Overall clinical characteristics, disease severity, and distribution of causes remained si

148 ce P. mirabilis urease activity and increase disease severity, and enhanced urease activity was the p

149 extracted and stratified by month, age, sex, disease severity, and enterovirus serotype.

150 tently observed across populations, seasons, disease severity, and geographical regions.

151 re matching (based on sex, age, comorbidity, disease severity, and previous reinterventions) was used

152 Neutrophilic airway inflammation, disease severity, and steroid resistance in human asthma

153 Levels of oxLDL ICs often correlate with disease severity, and studies demonstrated that oxLDL IC

154 relationship with cross-sectional markers of disease severity, and with future exacerbations, mortali

155 nts in demography, sites of involvement, and disease severity as determined by the degree of conjunct

156 ips between the presence of eye findings and disease severity as measured by the FOS Mainz severity s

157 serum concentrations of NfL correlated with disease severity, as assessed by striatal volume and bod

158 thermore, history of periodontal disease and disease severity, as well as its extent and a smoking ha

159 Disease severity at baseline, surgical incisions, suture

160 7; P=1.6x10(-7)) but not with cardiovascular disease severity at baseline.

161 al level and for differences in case mix and disease severity at the patient level.

162 a combination of change in classification of disease severity based on alveolar bone loss and tooth l

163 statistically significant relationship with disease severity (based on Psoriasis Area and Severity I

164 ere was good correlation between rankings of disease severity between the 2 cohorts (Spearman rank co

165 d competing risk models were used to compare disease severity between vaccinated and unvaccinated pat

166 increased the psychiatrists' CGI ratings of disease severity by 0.65 [0.27; 1.02] points.

167 of 5-lipoxygenase correlated with increased disease severity by histological evaluation and paw swel

168 ing experimental pancreatitis, and regulates disease severity by potently activating CTSB.

169 However, when images were ranked in order of disease severity (by average expert classification), the

170 ylation (+/-SD) significantly increased with disease severity (cervical intraepithelial neoplasia [CI

171 a multivariable model adjusting for baseline disease severity, change in visual acuity, age, gender,

172 statistical significance after adjusting for disease severity, chemoprophylaxis, drug resistance, and

173 : Using the CMTPedS as an outcome measure of disease severity, children with CMT progress at a signif

174 nificantly delayed disease onset and reduced disease severity compared with wild-type (Plg(+)) mice.

175 severe virus burden, BR/08 virus-associated disease severity correlated with extensive virus spread

176 Higher disease severity correlated with larger verbal memory de

177 in the independent cohorts, correlated with disease severity, corresponded to the most significantly

178 m provides recommendations for assessment of disease severity, data collection, and endpoint definiti

179 e and make recommendations for assessment of disease severity, data collection, and updated endpoint

180 ely debilitating syndromes in children, with disease severity dependent on the specific gene mutation

181 It is also possible that disease severity depends on the virulence of the chlamyd

182 Disease severity depends on whether the inflammatory res

183 s, people with FD show marked differences in disease severity despite carrying an identical, homozygo

184 association of NT-proBNP concentration with disease severity, discharge outcomes and prognosis of pa

185 Disease severity does not influence the response to syst

186 Depletion of CD11c(+) cells markedly reduced disease severity due to impaired enrichment of pathogeni

187 Disease severity (dyspnea, QoL, exacerbations, comorbidi

188 tomy) and 22 factors regarding demographics, disease severity (eg, Acute Physiology And Chronic Healt

189 L2, CCL3, and CCL4 have been associated with disease severity, endothelial dysfunction, and vasodilat

190 iomyopathy/dysplasia phenotype with variable disease severity expression, high-incidence of sudden ca

191 severe alcoholic hepatitis based on baseline disease severity, extent of therapeutic improvement, lon

192 This finding included differences in disease severity for which the only significant differen

193 care based on hospital volume stratified by disease severity, geography, and specialty.

194 ests were utilized to test differences among disease severity groups.

195 that this association was not independent of disease severity (hazard ratio, 0.95; 95% CI, 0.64-1.39;

196 Regardless, MF was associated with disease severity (ie, BNP) and outcomes.

197 While Th2 and Tc2 clustered with disease severity, IFN-gamma producing cells were linked

198 e-plus and plus disease at earlier stages of disease severity in 2016, compared with 2007.

199 (NTHI) ModA2 phasevarion on pathogenesis and disease severity in a chinchilla model of experimental o

200 We evaluated rs641738 influence on disease severity in a cohort of 1,101 patients with CHB.

201 racteristics, genotypes, and determinants of disease severity in a large patient cohort with EPP or X

202 creased overall urease activity in vitro and disease severity in a model of urinary tract infection (

203 JNJ0966 was efficacious in reducing disease severity in a mouse experimental autoimmune ence

204 gated the effect of influenza vaccination on disease severity in adults hospitalized with laboratory-

205 etween DTI findings and clinical measures of disease severity in ALS may partly be accounted for by c

206 ss extension, eosinophilic inflammation, and disease severity in asthmatic patients, metabolomics (us

207 pite high doses of corticosteroids indicates disease severity in asthmatic patients.

208 mice during the AOM/DSS treatment attenuated disease severity in CX3CR1(-/-) mice, indicating the imp

209 dy, we found that FXR knockout mice had more disease severity in experimental autoimmune encephalomye

210 to study the effects of parasite strains on disease severity in human infections, but the mechanisms

211 of specific retinal findings associated with disease severity in knowlesi malaria contrasts with the

212 of this inducible barrier in mice increased disease severity in models of neuroinflammation.

213 Our findings may allow an early prognosis of disease severity in mTLE before its first clinical manif

214 esterol clearance in macrophages and reduced disease severity in PAP mice.

215 1 and IL8 polymorphisms with changes in lung disease severity in patients with CF (n = 6365; IL8, P =

216 o determine whether NETs are associated with disease severity in patients with COPD and how they are

217 Furthermore, cardiac diseases contribute to disease severity in patients with COPD, being a common c

218 D pathogenesis are postulated to explain the disease severity in patients with HIV; these mechanisms

219 notype antibodies on protective immunity and disease severity in secondary infections.

220 e utility of skin biopsies as a biomarker of disease severity in subjects with amyloid neuropathy.

221 y the i-ROP system, may improve agreement on disease severity in the future.

222 , demographic features, disease duration, or disease severity in the whole population or within group

223 vin is elevated and strongly correlates with disease severity in two established murine models of acu

224 ndance of disease-modifying foliar fungi and disease severity in wild trees.

225 y antibodies directed to G, can modulate RSV disease severity in young infants.

226 strongly correlated with several markers of disease severity, including ratio of noncompacted to com

227 We tested a novel disease severity index generated by multivariate data an

228 The disease severity index identified eleven (13%) SMD indiv

229 The current disease severity index may have relevance for clinical p

230 Use of monetized disease severity information should be included in futur

231 The disease severity inversely correlates with the copy numb

232 However, quantification of disease severity is difficult, and published scores rema

233 Disease severity is IgE dose dependent and correlates wi

234 ted reductions in sialic acid production and disease severity is imperfect.

235 Disease severity is species dependent, ranging from mild

236 endothelial nitric oxide (NO) pathways with disease severity is unknown.

237 HBV e-antigen (HBeAg), a clinical marker for disease severity, is a soluble variant of the viral caps

238 he system accurately discriminated stages of disease severity (low to high): A (5-6 points), B (7-9),

239 ccelerometer output correlated with clinical disease severity markers and may predict outcome.

240 to investigate its correlation with clinical disease severity markers.

241 primary and secondary infection status, and disease severity, measured by plasma leakage.

242 ion of hospitalization, consciousness level, disease severity, medical cost, and the presence of do-n

243 on the outcome of the meta-analysis, whereas disease severity might be a confounding factor for the m

244 These data help to appreciate the range of disease severity observed in vivo and the occurrence of

245 lasting immunogenic memory, which determines disease severity of subsequent infections.

246 The impact of disease severity on the outcome after complete revascula

247 Staphylococcus aureus skin colonization, and disease severity on vaccine response.

248 No correlation with disease severity or asthma clinical features was identif

249 arospasm or hemifacial spasm correlates with disease severity or botulinum toxin treatment.

250 of potential unmeasured confounders such as disease severity or concomitant prescription of chemothe

251 fection, RAGE functions to either exacerbate disease severity or enhance pathogen clearance depending

252 There is no model to assess disease severity or progression or predict patient outco

253 as been identified between mutation type and disease severity or progression.

254 mipurified diet have significantly increased disease severity (P<0.001) and mortality (P < 0.001) com

255 heat three standardized approaches (Fusarium disease severity, PCR assays for Fusarium spp. identific

256 The loss of NLRX1 results in increased disease severity, populations of Th1 and Th17 cells, and

257 cellular and molecular mechanisms leading to disease severity progression.

258 clinical biomarker of FRDA as a correlate of disease severity, progression, and therapeutic effect.

259 and wild nonhuman primates, with associated disease severity ranging from apparently asymptomatic in

260 e good agreement between cohorts on relative disease severity ranking, the higher average score and c

261 Baseline disease severity, rate of visual field loss, and duratio

262 Levels of disease severity, relapse, and mortality were increased,

263 ppear highly specific to detect and quantify disease severity related to myocardial iron overload sta

264 causing increased viral transmissibility and disease severity requires experimental systems.

265 itis at disease onset significantly reversed disease severity, resulting in recovery from hindlimb pa

266 significant difference - SIT improved global disease severity RR 2.85 (95% CI 1.02, 7.96); and itch m

267 lus Score and the Clinical Global Impression Disease Severity Score but not sex (multivariate HR 0.93

268 ROP and suggests that a continuous ROP plus disease severity score may reflect more accurately the b

269 eveloped a secondary infection showed higher disease severity scores and higher mortality up to 1 yea

270 lyso-globotriaosylceramide levels and worse disease severity scores in patients.

271 ondition; and its expression correlated with disease severity scores, endotoxemia, infections, and sh

272 ibodies, were associated with lower clinical disease severity scores.

273 f ectopic R-loops, inversely correlates with disease severity scores.

274 Disease severity subgroup meta-analysis revealed a signi

275 h severe sepsis and septic shock in specific disease severity subgroups.

276 fluence on parameters not directly linked to disease severity such as gametocyte carriage and infecti

277 the IFN-signature positively correlates with disease severity, suggesting that type I IFNs are active

278 F, ECV was associated with baseline log BNP (disease severity surrogate) in multivariable linear regr

279 d host response during sepsis independent of disease severity, thereby providing clinical validity to

280 dystonia patients, which is correlated with disease severity, thereby supporting striatal plasticity

281 nt, which should be tailored on the basis of disease severity, underlying disease, and prior therapie

282 Kidney disease severity varies considerably and accurate inform

283 Improvement in psoriasis skin disease severity was associated with improvement in aort

284 Furthermore, increased disease severity was associated with lower levels of IL-

285 children was analyzed by flow cytometry, and disease severity was defined by standard criteria.

286 Disease severity was determined based on the percent wei

287 AE disease induction was delayed and reduced disease severity was observed.

288 Disease severity was scored using the Lund-Mackay scores

289 Disease severity was similar throughout ICU stay.

290 Blood glucose levels and disease severities were analyzed.

291 RSV infections representing the spectrum of disease severity were prospectively evaluated.

292 g for year of enrollment, age, etiology, and disease severity, whereas CRRT (odds ratio [OR], 0.47 [9

293 Lbh knockout exacerbated disease severity, which is associated with elevated leve

294 ter disease initiation significantly reduced disease severity, which was associated with a significan

295 oming and systemic subsets, correlating with disease severity, while IFN-gamma is linked to disease c

296 magnetic resonance imaging (MRI) measures of disease severity will help define their significance and

297 f eight cutaneous transcripts differentiates disease severity with a sensitivity and specificity of 9

298 tched-pair analysis of patients with similar disease severity with or without transplantation.

299 chanistic insight or an objective measure of disease severity, with their future role in risk stratif

300 es not appear to be associated with maternal disease severity, ZIKV-RNA load at time of infection or